This is the authors' abstract. We don't add key points for this paper.
Eleven dogs with cutaneous mast cell tumors (MCTs) were treated with surgery and iridium-192 ((192)Ir) interstitial brachytherapy. Minimum tumor doses ranged from 47.2 to 63.3 Gy. Treated tumors were classified as grade II (n=7) or III (n=4). Five dogs had recurrences with a median progression-free interval of 1391 days, and six dogs had no recurrence at a median follow-up time of 942 days. Acute adverse effects were well tolerated, and late effects were mild. One dog developed a second tumor of a different cell type in the radiation treatment field.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Northrup et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: